stockportfolio.pro
Stocks / ANGO vs PRME
ANGO vs PRME
AngioDynamics, Inc. and Prime Medicine, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AngioDynamics, Inc. (ANGO) | Prime Medicine, Inc. (PRME) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $292.50M | $4.63M |
| Net income (latest FY) | $-33.99M | $-201.14M |
| Revenue growth (5y CAGR) | 2.1% | -2.3% |
| Net margin | -11.6% | -4342.4% |
| Return on equity | -18.6% | -166.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANGO — free Open PRME — freeFrequently asked questions
Which is bigger, ANGO or PRME?
Prime Medicine, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, ANGO or PRME?
Over the last five fiscal years, AngioDynamics, Inc. grew revenue faster — 2.1%/yr versus -2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.